MAZE logo

MAZE
Maze Therapeutics Inc.

137
Mkt Cap
$1.41B
Volume
156,318.00
52W High
$53.65
52W Low
$9.16
PE Ratio
-10.05
MAZE Fundamentals
Price
$24.67
Prev Close
$25.56
Open
$25.77
50D MA
$33.02
Beta
0.96
Avg. Volume
897,241.23
EPS (Annual)
-$2.66
P/B
3.72
Rev/Employee
$0.00
$1,725.36
Loading...
Loading...
News
all
press releases
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares...
Yahoo! Finance: News·21h ago
News Placeholder
More News
News Placeholder
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts
Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given a consensus rating of "Buy" by the eleven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two ha...
MarketBeat·14d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total transaction of $190,275.00. Following the sale, the insider directly...
MarketBeat·17d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Here's Why
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Should You Buy...
MarketBeat·26d ago
News Placeholder
Maze Therapeutics Prices $150 Mln Stock, Pre-Funded Warrants Offering
(RTTNews) - Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Wednesday, announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds...
Nasdaq News: Markets·26d ago
News Placeholder
239,994 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Mass General Brigham Inc
Mass General Brigham Inc acquired a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·27d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·1mo ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading Volume - Here's What Happened
Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading Volume - Here's Why...
MarketBeat·1mo ago
News Placeholder
HC Wainwright Issues Optimistic Estimate for MAZE Earnings
Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Research analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for shares of Maze Therapeutics in a research report...
MarketBeat·1mo ago
<
1
2
...
>

Latest MAZE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.